{"filings":[{"id":442396,"accession_number":"0001628280-26-035068","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2026-05-14T20:03:27+00:00","items":["5.07"],"status":"ready","headline":"TriSalus annual meeting elects two directors, ratifies auditor, approves say-on-pay frequency","event_type":"other_material","confidence":"high","bullets":["Mary Szela and Gary Gordon elected to three-year director terms with ~92% for votes.","Grant Thornton LLP ratified as independent auditor for fiscal 2026.","Advisory vote on exec compensation approved; board adopts three-year frequency for future votes.","Turnout: 67.9% of outstanding shares represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":40121,"accession_number":"0001628280-26-034082","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2026-05-12T20:03:05+00:00","items":["2.02","9.01"],"status":"ready","headline":"TriSalus Q1 revenue $8.9M (-2.9% YoY); revises FY 2026 guidance to $54-57M","event_type":"earnings","confidence":"high","bullets":["Revenue $8.9M, down 2.9% YoY; gross margin improved to 86.2% from 83.7%.","Net income $1.5M ($0.03 EPS) on $11.3M non-cash derivative gains; adj. EBITDA loss $5.8M.","Raised $46M in equity; cash $56.6M to fund commercial expansion and pipeline.","2026 revenue guidance revised to $54-57M, reflecting commercial expansion and TriNav Advance FDA clearance delay.","Appointed Richard Marshall as Chief Medical Officer effective June 29, 2026; added board member Michael Stansky."],"consensus_eps_estimate":null,"consensus_eps_actual":0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":8899000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95894,"accession_number":"0001628280-26-028425","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"TriSalus Life Sciences Chief of Clinical Operations Jodi Devlin to retire October 1, 2026","event_type":"leadership","confidence":"high","bullets":["Jodi Devlin notified Company on April 24, 2026 of retirement as Chief of Clinical Operations.","Retirement effective October 1, 2026; Company expresses gratitude for her contributions.","Previously announced Dr. Richard Marshall as new Chief Medical Officer effective June 29, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95893,"accession_number":"0001628280-26-023991","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2026-04-07T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"TriSalus appoints Dr. Richard Marshall as CMO, effective June 29, 2026","event_type":"leadership","confidence":"high","bullets":["Annual base salary of $525,000; sign-on bonus of $250,000.","Eligible for annual bonus up to 50% of base salary based on board-determined goals.","Board will recommend granting 120,000 stock options and 60,000 restricted stock units.","Marshall, previously Medical Director since Jan 2025, will lead medical strategy and clinical development.","Appointment strengthens leadership as TriSalus advances its PEDD platform for solid tumors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109303,"accession_number":"0001628280-26-015155","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TriSalus Q4 revenue $13.2M (+60% YoY); reaffirms 2026 revenue guidance $60-62M","event_type":"earnings","confidence":"high","bullets":["Full-year 2025 revenue $45.2M (+53% YoY); Q4 gross margin 86.7% vs 85.3% prior year.","Adjusted EBITDA loss improved to $0.9M in Q4 2025 from $5.7M loss in Q4 2024.","Net loss attributable to common shareholders FY2025 $69.7M ($1.84 loss per share) vs $33.2M ($1.31) prior year.","Raised $46M gross proceeds from public offering post-Q4; cash and equivalents $20.4M at Dec 31, 2025.","Appointed Michael Stansky to board in Feb 2026; launched TriNav XP infusion system."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109302,"accession_number":"0001493152-26-007598","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2026-02-20T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"TriSalus prices $40M public offering of 9.76M shares at $4.10/share","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$40.0M from 9,756,100 shares at $4.10/share; net proceeds ~$37.0M (before over-allotment).","Underwriters granted 30-day option to purchase up to 1,463,415 additional shares (15% of offering).","Offering expected to close February 23, 2026; Lake Street Capital Markets sole book-runner.","Net proceeds estimated at ~$42.64M if over-allotment fully exercised.","Proceeds for general corporate purposes including working capital and G&A."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109301,"accession_number":"0001628280-26-006219","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2026-02-09T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"TriSalus Life Sciences appoints Michael Stansky to board, replacing Dr. Desai","event_type":"leadership","confidence":"high","bullets":["Dr. Arjun \"JJ\" Desai resigned from the board on February 3, 2026; no disagreement with the company.","Michael P. Stansky appointed to the board effective February 4, 2026.","Stansky brings 40 years of investment management and healthcare experience; former Managing Director at Tudor Investment Corp.","He will serve on the Audit, Compensation, and Science and Technology Committees.","Stansky currently serves on boards of Insightec and Momentis Surgical; past boards include Mako Surgical and Transmedics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109300,"accession_number":"0001628280-26-001743","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TriSalus reports Q4 revenue $13.2M (+60% YoY), FY25 $45.2M (+53%), FY26 guidance $60-62M","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue approx $13.2M vs $8.3M year ago, up 60% YoY; full-year revenue approx $45.2M vs $29.4M, up 53% YoY.","Revenue growth exceeded prior guidance of 50% annual growth for 2025.","Initial 2026 revenue guidance set at $60M to $62M.","Year-end cash approx $20.4M, down $2.3M from start of Q4 reflecting investment in growth."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":45151000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125792,"accession_number":"0001628280-25-052008","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TriSalus Q3 revenue $11.6M (+57% YoY); net loss $41.3M on preferred conversion; reaffirms 50% FY growth","event_type":"earnings","confidence":"high","bullets":["Revenue $11.6M, up 57% YoY and 3% sequentially; all from TriNav liver embolization.","Gross margin 84% vs 86% prior year; operating loss $9.0M vs $8.7M.","Net loss attributable to common $41.3M ($0.96 EPS) due to $30.5M preferred conversion charge.","Adjusted EBITDA loss improved to $5.4M from $7.2M; cash $22.7M with runway to positive adj. EBITDA.","Reaffirmed FY2025 revenue growth of at least 50%; initiated GAE trial for knee OA; published thyroid embolization data."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":31946000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125791,"accession_number":"0001628280-25-043440","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2025-10-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"TriSalus director Sean Murphy resigns from Board and Science Committee","event_type":"leadership","confidence":"high","bullets":["Sean Murphy resigned from the Board and the Science and Technology Committee effective September 30, 2025.","Resignation is not due to any disagreement with the Company's operations, policies, or practices.","Murphy served as a director and on the Science and Technology Committee of TriSalus Life Sciences.","The Company's stock trades on Nasdaq under the symbol TLSI."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142523,"accession_number":"0001826667-25-000129","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2025-08-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"TriSalus Life Sciences raises CFO base salary to $550K, grants performance-based stock options","event_type":"leadership","confidence":"high","bullets":["CFO David Patience's annual base salary increased from $450K to $550K, effective immediately.","Compensation Committee approved stock options for 249,899 shares at $5.11 per share.","Options vest upon company achieving ≥$75M revenue in any 12 consecutive months by Dec 31, 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142522,"accession_number":"0001826667-25-000115","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TriSalus Q2 revenue $11.2M (+52% YoY); reaffirms 50% FY growth; net loss $9.0M","event_type":"earnings","confidence":"high","bullets":["Revenue $11.2M, +52% YoY, +22% sequential; gross margin 84% vs 88%.","Operating loss improved to $7.3M from $8.2M; net loss $9.0M ($0.27 diluted EPS loss).","Reaffirmed FY2025 revenue growth at least 50%; cash $26.5M, runway to positive adj. EBITDA H1 2026.","Launched TriNav FLX for tortuous vessels; early sales exceeded internal projections.","Simplified capital structure via exchange of Series A Preferred stock completed post-quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":20380000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142521,"accession_number":"0001826667-25-000103","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2025-07-24T23:59:59+00:00","items":["3.03","5.03","5.07","8.01","9.01"],"status":"ready","headline":"TriSalus completes Preferred Stock exchange; 98.82% tendered at 3.3 common shares each","event_type":"other_material","confidence":"high","bullets":["Approximately 98.82% of outstanding Series A Convertible Preferred Stock (3,551,502 shares) validly tendered in exchange offer.","Each preferred share exchanged for 3.3 shares of common stock, based on a $4.00 per common share conversion price.","Amendment to Certificate of Designations filed July 24, 2025, enabling mandatory conversion of remaining preferred shares.","Settlement of all validly tendered shares expected on or before August 1, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160565,"accession_number":"0001826667-25-000077","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"TriSalus launches exchange offer for Series A Preferred, up to 11.9M common shares","event_type":"other_material","confidence":"high","bullets":["Offers up to 11,860,206 common shares in exchange for each share of Series A Convertible Preferred at $4.00 per share based on liquidation preference plus accrued dividends through Aug 10, 2027.","Consent solicitation seeks amendment to automatically convert remaining Preferred after offer closes at a ratio 11.3% lower than exchange offer.","Holders representing ~55% of outstanding Preferred have agreed to tender and consent via Tender and Support Agreements.","Expiration date: 12:01 a.m. ET on July 23, 2025; shares can be withdrawn anytime before.","3,594,002 Preferred shares outstanding as of June 13, 2025; Preferred stock not publicly traded."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160564,"accession_number":"0001826667-25-000074","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2025-06-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"TriSalus shareholders elect Wahlström and Matlin to board, ratify Grant Thornton","event_type":"other_material","confidence":"high","bullets":["Mats Wahlström and David J. Matlin elected to three-year terms with 20,002,109 and 20,005,151 votes for, respectively; 5,978,753 broker non-votes each.","Ratification of Grant Thornton as independent auditor for 2025: 26,445,528 for, 36,277 against, 994 abstain.","26,482,799 of 36,180,828 outstanding shares (73.2%) represented at the June 12, 2025 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160563,"accession_number":"0001826667-25-000071","cik":1826667,"company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSI","form_type":"8-K","filed_at":"2025-05-30T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"TriSalus Life Sciences appoints David Patience as CFO; James Young resigns","event_type":"leadership","confidence":"high","bullets":["CFO James Young resigned for personal reasons effective May 30, 2025; receives six months salary and continued equity vesting through May 2026.","David Patience appointed CFO effective July 1, 2025; base salary $450,000, sign-on bonus $159,000, eligible for 50% annual bonus and 1% stock option grant.","Dan Giordano, VP of Finance, serves as acting CFO during transition; Young remains available for orderly handover.","Patience previously CFO at Accelerate Diagnostics; also held roles at Morgan Stanley, Continental Advisors, and Nuveen Investments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}